Nemes Rush Group LLC increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 126,861 shares of the biopharmaceutical company's stock after purchasing an additional 10,189 shares during the period. Nemes Rush Group LLC's holdings in Pfizer were worth $3,366,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on PFE. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America reiterated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Finally, Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $31.92.
View Our Latest Stock Report on PFE
Insiders Place Their Bets
In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company's stock.
Pfizer Trading Up 0.8 %
Shares of NYSE:PFE traded up $0.19 during trading on Wednesday, hitting $24.73. 41,783,008 shares of the company's stock were exchanged, compared to its average volume of 39,216,666. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $140.26 billion, a P/E ratio of 17.54, a PEG ratio of 0.64 and a beta of 0.61. The firm has a 50-day moving average price of $26.00 and a two-hundred day moving average price of $26.84. Pfizer Inc. has a 1-year low of $24.33 and a 1-year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 EPS. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
